# A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

> **NCT04649151** · PHASE2,PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 4328 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** mRNA-1273.222

## Key facts

- **NCT ID:** NCT04649151
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2024-06-14
- **Final completion:** 2024-06-14
- **Target enrollment:** 4328 (ACTUAL)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649151, "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04649151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*